title: Clopidogrel and modified-release dipyridamole for the prevention of occlusive vascular events (NICE technology appraisal guidance 90).
abstract: The National Institute for Health and Clinical Excellence has recently published an update of technology appraisal guidance 90, first published in 2005, which evaluated the use of clopidogrel and modified-release dipyridamole for the prevention of occlusive vascular events. This article considers the update in detail and discusses the implications for clinical practice.
authors.affiliation: College of Medicine, Veterinary and Life Sciences, Institute of Cardiovascular and Medical Sciences, Western Infirmary, Glasgow, UK.
authors.forename: Kirsty
authors.initials: K
authors.lastname: Stewart
authors.forename: Matthew
authors.initials: M
authors.lastname: Walters
authors.forename: Jesse
authors.initials: J
authors.lastname: Dawson
mesh_terms: D001241:Aspirin / Q000627:therapeutic use; D000077144:Clopidogrel; D003251:Constriction, Pathologic / Q000517:prevention & control; D003692:Delayed-Action Preparations; D004176:Dipyridamole / Q000008:administration & dosage / Q000627:therapeutic use*; D016568:Drugs, Generic / Q000627:therapeutic use; D006801:Humans; D010975:Platelet Aggregation Inhibitors / Q000008:administration & dosage / Q000627:therapeutic use*; D017410:Practice Guidelines as Topic; D013988:Ticlopidine / Q000031:analogs & derivatives* / Q000627:therapeutic use; D014652:Vascular Diseases / Q000517:prevention & control*
chemical_list: D003692:Delayed-Action Preparations; D016568:Drugs, Generic; D010975:Platelet Aggregation Inhibitors; D004176:Dipyridamole; D000077144:Clopidogrel; D013988:Ticlopidine; D001241:Aspirin